Zevra Therapeutics (ZVRA) Stock Analysis & Winston Score

Zevra Therapeutics is a small biotech company that makes medicines for rare diseases — conditions that affect very few people and often have no other treatment options. Its main approved drug is Miplyffa (arimoclomol), which treats Niemann-Pick disease type C, a rare and life-threatening brain disorder. The company focuses on patients with serious unmet medical needs, mostly in the United States. Zevra earns money by selling its approved drug directly to patients and specialty pharmacies, which explains its high gross margin of around 85%. The company operates primarily in the US and is still relatively small, with a market cap near $600 million. Its competitive position comes from orphan drug designations, which give it market exclusivity and make it harder for competitors to enter its niche. However, Zevra is currently spending more than it earns — its negative operating margin reflects heavy investment in research and development — so its main risk is whether it can grow revenue fast enough to reach profitability.